Education
About Us
Working with TipRanks
Follow Us
Agios Pharma (AGIO)
NASDAQ:AGIO
AGIO Stock Chart & Stats
Day’s Range― - ―
52-Week Range$23.42 - $62.58
Previous CloseN/A
Volume212.48K
Average Volume (3M)735.06K
Market Cap
$2.26B
Enterprise Value$1.04B
Total Cash (Recent Filing)$938.94M
Total Debt (Recent Filing)$48.76M
Price to Earnings (P/E)3.5
Beta1.70
Next Earnings
Oct 30, 2025EPS Estimate
-1.9Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-1.93
Shares Outstanding58,101,517
10 Day Avg. Volume645,684
30 Day Avg. Volume735,063
Financial Highlights & Ratios
PEG Ratio>-0.01
Price to Book (P/B)1.21
Price to Sales (P/S)51.14
P/FCF Ratio-4.77
Enterprise Value/Market Cap0.46
Enterprise Value/Revenue25.36
Enterprise Value/Gross Profit29.80
Enterprise Value/Ebitda-2.34
Forecast
1Y Price Target
$51.33Price Target Upside31.85% Upside
Rating ConsensusModerate Buy
Number of Analyst Covering7
Bulls Say, Bears Say
Bulls Say
Analyst ConfidenceThe analyst maintains a buy rating with a price objective above the current price, indicating confidence in the stock's potential growth.
FDA ApprovalThe PDUFA extension suggests the FDA is likely to approve mitapivat in thalassemia after agreeing on the appropriate mitigation strategy.
International ApprovalBroad approval in Saudi Arabia without additional requirements has been viewed positively by many investors regarding US approval.
Bears Say
Commercial ImplicationsPayers may also consider restricting access until they can better understand the implications and management of the REMS.
Market ReactionThe company's stock experienced a significant drop, seen as an overreaction to the PDUFA delay.
Regulatory ChallengesThe extension of the PDUFA date was due to concerns about hepatocellular injury, leading to a decrease in stock price.
Agios Pharma News
AGIO FAQ
What was Agios Pharma’s price range in the past 12 months?
Agios Pharma lowest stock price was $23.41 and its highest was $62.58 in the past 12 months.
What is Agios Pharma’s market cap?
Agios Pharma’s market cap is $2.26B.
When is Agios Pharma’s upcoming earnings report date?
Agios Pharma’s upcoming earnings report date is Oct 30, 2025 which is in 30 days.
How were Agios Pharma’s earnings last quarter?
Agios Pharma released its earnings results on Jul 31, 2025. The company reported -$1.93 earnings per share for the quarter, missing the consensus estimate of -$1.807 by -$0.123.
Is Agios Pharma overvalued?
According to Wall Street analysts Agios Pharma’s price is currently Undervalued.
Does Agios Pharma pay dividends?
Agios Pharma does not currently pay dividends.
What is Agios Pharma’s EPS estimate?
Agios Pharma’s EPS estimate is -1.9.
How many shares outstanding does Agios Pharma have?
Agios Pharma has 58,101,517 shares outstanding.
What happened to Agios Pharma’s price movement after its last earnings report?
Agios Pharma reported an EPS of -$1.93 in its last earnings report, missing expectations of -$1.807. Following the earnings report the stock price went down -0.852%.
Which hedge fund is a major shareholder of Agios Pharma?
Currently, no hedge funds are holding shares in AGIO
Agios Pharma Stock Smart Score
Neutral
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Moderate Buy
Average Price Target:
$51.33 (31.85% Upside)
$51.33 (31.85% Upside)
Blogger Sentiment
Bullish
AGIO Sentiment 100%
Sector Average 72%
Sector Average 72%
Hedge Fund Trend
Increased
By 400.7K Shares
Last Quarter.
Last Quarter.
Insider Transactions
Sold Shares
Worth $315.1K over
the Last 3 Months
the Last 3 Months
Crowd Wisdom
Very Positive
Last 7 Days ▲ 6.0%
Last 30 Days ▲ 5.9%
Last 30 Days ▲ 5.9%
News Sentiment
Very Bearish
Bullish news 19%
Bearish news 100%
Bearish news 100%
Technicals
SMA
Positive
20 days / 200 days
Momentum
-18.98%
12-Months-Change
Fundamentals
Return on Equity
64.05%
Trailing 12-Months
Asset Growth
90.31%
Trailing 12-Months
Company Description
Agios Pharma
Agios Pharmaceuticals, Inc., a biopharmaceutical company, engages in the discovery and development of medicines in the field of cellular metabolism and adjacent areas of biology. The company offers PYRUKYND (mitapivat) an activator of both wild-type and a variety of mutant pyruvate kinase, PK, enzymes for the treatment of hemolytic anemias; and AG-946 that is in Phase I clinical study for treating hemolytic anemias and other indications. Agios Pharmaceuticals, Inc. was incorporated in 2007 and is headquartered in Cambridge, Massachusetts.
AGIO Company Deck
AGIO Earnings Call
Q2 2025
0:00 / 0:00
Earnings Call Sentiment|Positive
The earnings call presented a generally positive outlook with strong revenue growth for PYRUKYND, advancements in regulatory approvals, and strategic partnerships to expand global reach. However, there were also concerns about revenue variability, increased expenses, and challenges in market expansion, which could temper expectations. Overall, the highlights outweigh the lowlights, suggesting a positive sentiment.View all AGIO earnings summariesAGIO Stock 12 Month Forecast
Average Price Target
$51.33
▲(31.85% Upside)
Technical Analysis
ImmunityBio
―
Denali Therapeutics
―
NewAmsterdam Pharma Company
―
Recursion Pharmaceuticals
―
Apogee Therapeutics
―
Ownership Overview
0.85% Insiders
25.95% Mutual Funds
0.07% Other Institutional Investors
55.82% Public Companies and
Individual Investors